Literature DB >> 3120505

The anti-inflammatory pharmacologic profile of CGP 28237 (5-methylsulfonylamino-6-phenoxy-1-indanone).

I Böttcher1, B Jagher, C Rordorf-Adam, M Grüninger.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120505     DOI: 10.1007/bf01966476

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


× No keyword cloud information.
  7 in total

1.  Effects of oral aspirin and oxaprozin on the development of lupus-like disease in MRL/1 mice.

Authors:  R P Carlson; S C Gilman; T G Hodge; L O'Neill-Davis; E M Blazek; A J Lewis
Journal:  J Immunopharmacol       Date:  1984

2.  Correlation between the rise in acute phase proteins and histological evidence of ulceration in the rat following indomethacin treatment [proceedings].

Authors:  M E Billingham; M J Tucker
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

3.  The usability of the MRL/1 mouse strain in detection of anti-rheumatic drugs.

Authors:  M L Toivonen; I B Lindén; M Gripenberg; H Vapaatalo
Journal:  Agents Actions       Date:  1984-12

4.  Serum amyloid P component and autoimmune parameters in the assessment of arthritis activity in MRL/lpr/lpr mice.

Authors:  C Rordorf-Adam; D Serban; A Pataki; M Grüninger
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

5.  A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats.

Authors:  I Böttcher; A Schweizer; M Glatt; H Werner
Journal:  Drugs Exp Clin Res       Date:  1987

6.  Quantitation of serum amyloid P component by an enzyme-linked immunoassay.

Authors:  D Serban; C Rordorf-Adam
Journal:  J Immunol Methods       Date:  1986-06-24       Impact factor: 2.303

7.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.